Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks ...

iTeos Therapeutics has agreed to be acquired by privately held Concentra Biosciences in a deal initially worth roughly $385 million. iTeos on Monday said Concentra will pay nearly $10.05 a share in ...

--iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported ...

“iTeos is entering 2023 from a position of strength. We are thoughtfully and methodologically advancing both our lead programs through clinical development to fully unlock their potential.

Turning to iTeos Therapeutics' balance sheet, the company had cash and cash equivalents of $216.2M, short-term investments of $383.0M, and long-term investments of $78.3M as of June 30, 2023.

Shares of iTeos Therapeutics Inc. soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline to develop and commercialize an experimental cancer therapy.

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a ...